Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736656 · ClinicalTrials.gov registry record · Phase 3
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
A Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Supernus Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,400
- Enrollment target
- 16
- Study locations
NCT02736656: Active Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Supernus Pharmaceuticals.
NCT02736656 is a Phase 3 study of Attention Deficit Hyperactivity Disorder that is active but no longer recruiting, run by Supernus Pharmaceuticals. The registered enrollment target is 1,400 participants, above the 203-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (590% higher). The trial reports 16 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02736656, a Phase 3 study of Attention Deficit Hyperactivity Disorder, is active but no longer recruiting, sponsored by Supernus Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,400 participants
- Enrollment target
- 16
- Study locations
Study Summary
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
Primary Outcome
The incidence (percentage of subjects dosed) of adverse events by System Organ Class and Preferred term by cohort
Conditions Studied
Interventions
- DRUG SPN-812
Study Locations (16)
Florida
- Meridien Research at Florida Clinical Research Center - Bradenton
- Sarkis Clinical Trials - Gainesville
- Indago Research & Health Center, Inc. - Hialeah
- Florida Clinical Research Center, LLC. - Maitland
- Florida Clinical Research Center, LLC - Maitland
Oklahoma
- IPS Research - Oklahoma City
- Paradigm Research Professionals - Oklahoma City
Tennessee
- Clinical Neuroscience Solutions, Inc. - Memphis
- CNS Healthcare - Memphis
Texas
- Bayou City Research Corporation - Houston
- Road Runner Research - San Antonio
Arkansas
- Woodland International Research Group - Little Rock
California
- Alliance for Wellness dba Alliance for Research - Long Beach
Colorado
- MCB Clinical Research Centers, LLC - Colorado Springs
Utah
- Ericksen Research & Development - Clinton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What the registry record for NCT02736656 still lists
NCT02736656 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, above the 203-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (590% higher).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which SPN-812 is the first listed.
NCT02736656 lists 16 locations in 9 states (Florida, Oklahoma, Tennessee).
Frequently Asked Questions
What is clinical trial NCT02736656 about?
NCT02736656 is a clinical study titled "Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)". Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
What is the current status of trial NCT02736656?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,400 participants. The study started on 2016-02-02. Estimated completion is 2026-09.
What conditions does trial NCT02736656 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT02736656?
The interventions under investigation include: SPN-812 (DRUG).
Who is sponsoring clinical trial NCT02736656?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02736656 being conducted?
This trial has 16 study locations across Arkansas, California, Colorado, Florida, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02736656's enrollment target sits among peer trials
1,400 2nd of 102 the highest of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI